Citations

Clear

299 citation(s) found for "Solomon, B".

Abstract MP77: Associations Between Atrial Cardiopathy and Cerebral Amyloid: The Aric Pet Study
Johansen, Michelle C. , Wong, Dean, Wagenknecht, Lynne E. , Ndumele, Chiadi E. , Solomon, Scott D. , Johansen, Michelle C , Mosley, Thomas H. , Knopman, David S. , Shah, Amil M. , Solomon, Scott David , Gottesman, Rebecca F.

Mayo Clinic

Circulation | March 2, 2020 | Volume: 141 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.141.suppl_1.mp77 Get It

Background: Atrial fibrillation (AF) is a risk factor for cognitive decline, perhaps due to silent cerebral infarction, but it is unknown if it also acts on Alzheimer’s Disease (AD)-specific mechanisms, such as deposition of β-amyloid (Aβ). Left atrial changes in structure or function, or atrial cardiopathy, can lead to AF but may cause infarcts independently, and thus might also impact cognition. We hypothesize that Aβ is associated with AF and atrial cardiopathy, independent of AF, when defined similarly to an ongoing clinical trial (ARCADIA). Methods: 321 participants without dementia from the Atherosclerosis Risk in Communities study underwent florbetapir (FBP) PET, electrocardiogram and 2D echocardiography. Atrial cardiopathy was defined as ≥1 of: 1) left atrial volume index (LAVI) >34 ml/m2; 2) P-wave terminal force >5000 uV x ms and 3) serum NT proBNP>250 pg/mL. Cross-sectional associations between global cortical Aβ (>1.2 standardized uptake value ratio (SUVR)) and adjudicated history of atrial fibrillation and atrial cardiopathy, each, were evaluated using multivariable logistic regression. Results: Participants, with mean age 76 y, were 56% female and 42% black. Odds of elevated FBP SUVR was increased for those with atrial cardiopathy (Model 3) and nearly doubled among those with enlarged LAVI that remained significant after sequential adjustment, including AF (Table). There was no significant association between either P-wave terminal force or NT proBNP and elevated FBP SUVR (Table), nor between elevated SUVR and AF. Conclusions: In this cross-sectional analysis of a cohort of healthy, nondemented community-dwelling older individuals, we report a significant association between atrial cardiopathy as well as LAVI and elevated amyloid, by PET, without a similar association in individuals with AF. Potential limitations include reverse causation and survival bias. Ongoing work will help determine if changes in cardiac structure and function precede, or occur simultaneously with amyloid deposition.
Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis
Smallridge, Robert C., Burman, KD, Porter, Lynne E., Cranston, Treena, Sfikakis, P.P., Solomon, Barbara, Tsokos, George C. , Porter, L

Mayo Clinic

Clinical Diagnostic Laboratory Immunology | January 6, 2020 | Volume: 4 | Issue: 5 | Pages: 583-586

10.1128/cdli.4.5.583-586.1997 | PMID 9302209 Get It

Thyrotoxic patients exhibit increased levels of immune activation molecules (soluble interleukin-2 receptor [sIL-2R], intercellular adhesion molecule-1 [ICAM-1], and endothelial-leukocyte adhesion molecule-1 [ELAM-1]) in serum, although the clinical significance of these measurements remains unclear. In a randomized 4-week study, we have recently shown that in the treatment of hyperthyroidism, the combination of cholestyramine and methimazole (MMI) resulted in faster lowering of serum thyroid-hormone levels than did MMI alone. Stored serial serum samples from patients participating in this randomized treatment trial were analyzed for sIL-2R, soluble ICAM-1 (sICAM-1), and soluble ELAM-1 (sELAM-1). The levels of all three molecules were elevated in patients with hyperthyroidism. Although the levels of sICAM-1 and sELAM-1 remained elevated through the 4-week follow-up period in both groups of patients, the sIL-2R levels (normal levels, 1.0 to 4.2 ng/ml) decreased significantly in the 10 patients who received cholestyramine in addition to MMI (week 0, 14.2 +/- 1.5 ng/ml; week 2, 10.8 +/- 1.2 ng/ml; week 4, 8.9 +/- 1.5 ng/ml). In eight patients who received MMI alone, sIL-2R decreased less rapidly (week 0, 12.3 +/- 1.4 ng/ml; week 2, 12.3 +/- 1.3 ng/ml; week 4, 10.9 +/- 1.3 ng/ml). sICAM-1 and sELAM-1 were elevated at baseline but did not decrease during therapy. In the former group, free thyroxine and free triiodothyronine decreased faster. These data show that levels of sIL-2R in serum, but not those of sICAM-1 and sELAM-1, may be of clinical use in the early follow-up evaluation of medically treated patients.
A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
Zhong, Jun, Jermusyk, Ashley , Wu, Lang , Hoskins, Jason W. , Collins, Irene , Mocci, Evelina , Song, Lei , Chung, Charles C., Xiao, Wenming , Andreotti, Gabriella , Arslan, Alan A. , Babić, Ana , Berndt, Sonja, Borgida, Ayelet , Bracci, Paige M. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Childs, Erica J., Du, Mengmeng , Fuchs, Charles S. , Gallinger, Steven , Gaziano, J. Michael, Giovannucci, Edward L. , Goodman, Gary E. , Goodman, Phyllis J. , Haiman, Christopher, Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Holly, Elizabeth A., Klein, Eric A. , Kogevinas, Manolis, Kurtz, Robert J., Ng, Kimmie , Obazee, Ofure , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Sieri, Sabina , Tjønneland, Anne , Thornquist, Mark, Trichopoulou, Antonia , Visvanathan, Kala , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yuan, Chen , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Brown, Kevin M. , Jacobs, Eric J. , Li, Donghui , Yu, Kai , Wolpin, Brian M. , Chatterjee, Nilanjan , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Arslan, Alan A , Tjønneland, Anne , Wactawski-Wende, Jean , Visvanathan, Kala , Klein, Eric A , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Zhong, Jun , Yuan, Chen , Hoskins, Jason W , Zhang, Mingfeng , Zhang, Tongwu , Albanes, Demetrius , Bamlet, William R. , Freeman, Laura E. Beane , Brais, Lauren K , Canzian, Federico , Cotterchio, Michelle , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Marchand, Loı̈c Le , Malats, Núria , Männistö, Satu , Milne, Roger L. , Neale, Rachel Ε. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Van Den Eeden, Stephen K , White, Emily , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Shu, Xiao‐Ou , Chanock, Stephen Jacob , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Kraft, Peter , Zheng, Wei , Ámundadóttir, Laufey T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 31, 2019 | Volume: 112 | Issue: 10 | Pages: 1003-1012

10.1093/jnci/djz246 | PMID 31917448 Get It

Abstract Background Although 20 pancreatic cancer susceptibility loci have been identified through genome-wide association studies in individuals of European ancestry, much of its heritability remains unexplained and the genes responsible largely unknown. Methods To discover novel pancreatic cancer risk loci and possible causal genes, we performed a pancreatic cancer transcriptome-wide association study in Europeans using three approaches: FUSION, MetaXcan, and Summary-MulTiXcan. We integrated genome-wide association studies summary statistics from 9040 pancreatic cancer cases and 12 496 controls, with gene expression prediction models built using transcriptome data from histologically normal pancreatic tissue samples (NCI Laboratory of Translational Genomics [n = 95] and Genotype-Tissue Expression v7 [n = 174] datasets) and data from 48 different tissues (Genotype-Tissue Expression v7, n = 74–421 samples). Results We identified 25 genes whose genetically predicted expression was statistically significantly associated with pancreatic cancer risk (false discovery rate < .05), including 14 candidate genes at 11 novel loci (1p36.12: CELA3B; 9q31.1: SMC2, SMC2-AS1; 10q23.31: RP11-80H5.9; 12q13.13: SMUG1; 14q32.33: BTBD6; 15q23: HEXA; 15q26.1: RCCD1; 17q12: PNMT, CDK12, PGAP3; 17q22: SUPT4H1; 18q11.22: RP11-888D10.3; and 19p13.11: PGPEP1) and 11 at six known risk loci (5p15.33: TERT, CLPTM1L, ZDHHC11B; 7p14.1: INHBA; 9q34.2: ABO; 13q12.2: PDX1; 13q22.1: KLF5; and 16q23.1: WDR59, CFDP1, BCAR1, TMEM170A). The association for 12 of these genes (CELA3B, SMC2, and PNMT at novel risk loci and TERT, CLPTM1L, INHBA, ABO, PDX1, KLF5, WDR59, CFDP1, and BCAR1 at known loci) remained statistically significant after Bonferroni correction. Conclusions By integrating gene expression and genotype data, we identified novel pancreatic cancer risk loci and candidate functional genes that warrant further investigation.
A Nipple-Areola Stencil for Three-Dimensional Tattooing: Nipple by Number
Azouz, Solomon M., Swanson, Marco , Omarkhil, Mirwais, Rebecca, Alanna M. , Azouz, Solomon, Rebecca, Alanna

Mayo Clinic

Plastic & Reconstructive Surgery | December 24, 2019 | Volume: 145 | Issue: 1 | Pages: 38-42

10.1097/prs.0000000000006398 | PMID 31881601 Get It

Summary: Medical tattooing is a critical reconstructive component in women following mastectomy. Recently, novel three-dimensional tattooing techniques mimicking depth by using light and shadow principles have allowed for aesthetically superior results. However, results are variable between providers, and professionals skilled in tattooing are often inaccessible to patients. To assess the need and obtain more background information regarding current practices, the authors recorded survey results from 753 plastic and reconstructive surgery offices. Results showed that 23 percent of facilities that offer reconstruction do not perform or refer for nipple-areola complex tattooing, leaving the patients to seek the service on their own. In this article, the authors present the nipple-by-number device, a three-dimensionally–printed stencil to ensure an accurate, consistent, and personalized aesthetic result during three-dimensional nipple-areola complex tattooing. The nipple-by-number device permits the plastic surgeon or supervised treating specialist to inexpensively, efficiently, and expeditiously perform the three-dimensional nipple-areola complex tattooing in their office. Furthermore, the device gives the patients the option of having their premorbid nipple-areola complex anatomy restored through preoperative photographs or choosing a different nipple-areola complex from a catalogue of designs. The device can be applied on any reconstructed breast mound whether or not a nipple projection procedure has been performed.
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction
McMurray, John J.V. , Jackson, Alice M. , Redfield, Margaret M. , Lefkowitz, Marty , Maggioni, Aldo P. , Martínez, Felipe A. , Pieske, Burkert , Rizkala, Adel R. , Sabarwal, Shalini V., Shah, Amil M. , Shi, Victor , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Zile, Michael R. , Čikeš, Maja , Gonçalvesová, Eva , Katova, Tzvetana, Kosztin, Anamaria, Lelonek, Małgorzata , Sweitzer, Nancy K. , Claggett, Brian , Solomon, Scott D. , Felker, G. Michael , Kosztin, Annamária , Zile, Michael R , Maggioni, Aldo P , McMurray, John J V , Shah, Amil , Lam, Carolyn S.P. , Anand, Inder S. , Ge, Junbo , Packer, Milton , Pfeffer, Marc Alan , Shah, Sanjiv J , Vardeny, Orly , Jhund, Pardeep S. , Solomon, Scott David

Mayo Clinic

Circulation | November 17, 2019 | Volume: 141 | Issue: 5 | Pages: 338-351

10.1161/circulationaha.119.044491 | PMID 31736337 Get It

Background: Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the predominant phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women compared with men. Methods: In a prespecified subgroup analysis, we examined outcomes according to sex in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction), which compared sacubitril-valsartan and valsartan in patients with heart failure with preserved ejection fraction. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and death from cardiovascular causes. We also report secondary efficacy and safety outcomes. Results: Overall, 2479 women (51.7%) and 2317 men (48.3%) were randomized. Women were older and had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP (N-terminal pro–B-type natriuretic peptide) levels than men. For the primary outcome, the rate ratio for sacubitril-valsartan versus valsartan was 0.73 (95% CI, 0.59–0.90) in women and 1.03 (95% CI, 0.84–1.25) in men ( P interaction = 0.017). The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. The improvement in New York Heart Association class and renal function with sacubitril-valsartan was similar in women and men, whereas the improvement in Kansas City Cardiomyopathy Questionnaire clinical summary score was less in women than in men. The difference in adverse events between sacubitril-valsartan and valsartan was similar in women and men. Conclusions: As compared with valsartan, sacubitril-valsartan seemed to reduce the risk of heart failure hospitalization more in women than in men. Whereas the possible sex-related modification of the effect of treatment has several potential explanations, the present study does not provide a definite mechanistic basis for this finding. Clinical Trial Registration: https://www.clinicaltrials.gov . Unique identifier: NCT01920711.
Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry
Berg, David D. , Barnett, Christopher F. , Kenigsberg, Benjamin B. , Papolos, Alexander , Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bohula, Erin A. , Brennan, Joseph , Burke, James A. , Cremer, Paul , Daniels, Lori B. , DeFilippis, Andrew P. , Granger, Christopher B. , Hollenberg, Steven M. , Horowitz, James M. , Gladden, James D., Katz, Jason N. , Keeley, Ellen C. , Keller, Norma , Kontos, Michael C. , Lawler, Patrick R. , Menon, Venu , Metkus, Thomas S. , Miller, P. Elliott , Nativi-Nicolau, José , Newby, L. Kristin , Park, Jeong-Gun, Phreaner, Nicholas , Roswell, Robert O. , Schulman, Steven P. , Snell, R. Jeffrey, Solomon, Michael A. , Teuteberg, Jeffrey J. , Tymchak, Wayne , Morrow, David A. , Lawler, Patrick , Solomon, Michael A , Morrow, David A , Granger, Christopher B , Roswell, Robert O , Daniels, Lori B , Bohula, Erin A , Cremer, Paul C , Berg, David , Burke, James A., Carnicelli, Anthony , Chaudhry, Sunit‐Preet , Gerber, Daniel , Park, Jeong‐Gun , Sinha, Shashank S , Diepen, Sean van

Mayo Clinic

Circulation: Heart Failure | November 11, 2019 | Volume: 12 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.119.006635 | PMID 31707801 Get It

Background: Temporary mechanical circulatory support (MCS) devices provide hemodynamic assistance for shock refractory to pharmacological treatment. Most registries have focused on single devices or specific etiologies of shock, limiting data regarding overall practice patterns with temporary MCS in cardiac intensive care units. Methods: The CCCTN (Critical Care Cardiology Trials Network) is a multicenter network of tertiary CICUs in North America. Between September 2017 and September 2018, each center (n=16) contributed a 2-month snapshot of consecutive medical CICU admissions. Results: Of the 270 admissions using temporary MCS, 33% had acute myocardial infarction-related cardiogenic shock (CS), 31% had CS not related to acute myocardial infarction, 11% had mixed shock, and 22% had an indication other than shock. Among all 585 admissions with CS or mixed shock, 34% used temporary MCS during the CICU stay with substantial variation between centers (range: 17%–50%). The most common temporary MCS devices were intraaortic balloon pumps (72%), Impella (17%), and veno-arterial extracorporeal membrane oxygenation (11%), although intraaortic balloon pump use also varied between centers (range: 40%–100%). Patients managed with intraaortic balloon pump versus other forms of MCS (advanced MCS) had lower Sequential Organ Failure Assessment scores and less severe metabolic derangements. Illness severity was similar at high- versus low-MCS utilizing centers and at centers with more advanced MCS use. Conclusions: There is wide variation in the use of temporary MCS among patients with shock in tertiary CICUs. While hospital-level variation in temporary MCS device selection is not explained by differences in illness severity, patient-level variation appears to be related, at least in part, to illness severity.
Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.
Solomon, Benjamin , Moreira, Jonathan , Schwager, Susan M., Call, Timothy G. , Rabe, Kari G. , Cerhan, James R. , Kay, Neil E. , Slager, Susan L. , Shanafelt, Tait D.

Mayo Clinic

Blood | October 11, 2019 | Volume: 120 | Issue: 21 | Pages: 2893-2893

10.1182/blood.v120.21.2893.2893 Get It

Abstract Abstract 2893 Introduction: Monoclonal B-Cell Lymphocytosis (MBL) is a common asymptomatic condition characterized by a clonal B-cell population detected in the blood or bone marrow. The prevalence of MBL is approximately 3–5% in adults over age 40 but rises with age. MBL is a precursor state to CLL and other types of indolent non-Hodgkin lymphoma (NHL). Only a small subset of patients with MBL comes to clinical attention, typically during evaluation for low grade lymphocytosis (designated now as clinical MBL). The rate of progression to CLL requiring treatment among individuals with clinical MBL is ∼1%/yr, and the vast majority of patients with MBL will never develop a B-cell malignancy. Recent data indicate that individuals with MBL are at increased risk of infection similar to CLL. It is unknown whether individuals with MBL are at risk for other adverse outcomes associated with CLL, such as increased risk of non-hematologic cancers (NHC). We investigated the incidence of NHC among patients with clinical MBL and compared this to a cohort of general medicine patients and a cohort of CLL patients. Methods: Mayo Clinic Rochester (MCR) is the primary center for hematologic care in a region including southeastern Minnesota, northern Iowa, and western Wisconsin. No other hematology specialty centers are available within a 50 mile radius of MCR. To explore the risk of NHC in a local, community dwelling cohort of individuals with clinically-identified, CLL-phenotype MBL, we used the MCR CLL database to identify all individuals with newly diagnosed MBL seen in the MCR Hematology Division between January 1, 1999 and December 31, 2009. Analysis was limited to 154 MBL cases residing within 50 miles of MCR. The comparison cohort consisted of 596 adult general medicine patients, with no prior cancer, residing within 50 miles of MCR, who were seen for a general medical exam and enrolled as controls in a case-control study for NHL between April 25, 2004 and December 31, 2009. Rates of NHC in the MBL cohort were also compared to a cohort of 174 patients with newly diagnosed CLL seen in the same time interval as the MBL cohort and also living within 50 miles of MCR. NHC were identified using the Mayo Clinic Cancer Tumor Registry as well as review of medical records in all 3 cohorts. Patients with a NHC diagnosis >3 months prior to the diagnosis date of MBL/CLL were excluded from analysis while those with MBL/CLL and a NHC within 3 months of one another were considered to have a concurrent diagnosis. Results: There were 125 patients in the MBL cohort, 153 in the CLL cohort, and 596 in the control cohort after excluding patients with prior cancers. The MBL and CLL patients tended to be older (median age MBL=69, CLL=68, Control=58; p<0.0001) and more likely to be male (% male MBL=61, CLL=67, Control=46; p<0.0001) than the controls. After a median follow-up of 4.2 years (range 0–11), 20 (16%) individuals with MBL developed NHC as compared to 22 (4%) of the controls (Hazard Ratio (HR) MBL relative to control=5.0; 95% confidence interval (CI)=(2.6, 9.4; p<0.0001). Twenty CLL patients (13%) developed NHC, supporting a similar rate to that of MBL patients (HR MBL relative to CLL=1.3; 95% CI=(0.6, 2.5; p=0.49;See Figure). Specifically, the MBL cohort had a higher incidence of cancer of the breast, lung, and nervous system than that of the control cohort. The higher risk of NHC among individuals with CLL and MBL persisted even when patients with “concurrent diagnosis” of CLL/MBL and NHC were excluded (p=0.006) and when patients treated for progressive CLL were censored at the date of treatment (p=0.001) Finally, we performed a pooled multivariable analysis of all patients (n=874) adjusting for age, sex, major co-morbidities, presence of MBL, and diagnosis of CLL. Age (HR each year older=1.03; 95% CI 1.01–1.06; p=0.003), major comorbidities (HR=1.81; 95% CI 1.07–3.00; p=0.02), CLL (HR=2.10; 95% CI 1.01–4.01; p=0.04), and MBL (2.47; 95% CI 1.30–4.69; p=0.02) were independent risk factors for NHC. The results were similar when the effects of age was modeled in a non-linear (e.g. logarithmic) manner. Conclusions: In this cohort study, patients with newly diagnosed clinical MBL had a 2.5-fold increased risk of developing NHC relative to the control cohort. MBL was an independent risk factor for development of NHC after adjusting for age, sex, and other comorbidities. This finding adds to the growing evidence that clinical MBL has a distinct clinical phenotype. Disclosures: Shanafelt: Genentech: Research Funding; Glaxo-Smith-Kline: Research Funding; Cephalon: Research Funding; Hospira: Research Funding; Celgene: Research Funding; Polyphenon E International: Research Funding.
Associations Between Left Ventricular Structure, Function, and Cerebral Amyloid
Johansen, Michelle C. , Wong, Dean F. , Wagenknecht, Lynne E. , Shah, Amil M. , Solomon, Scott D. , Johansen, Michelle C , Shah, Amil , Mosley, Thomas H. , Knopman, David S. , Solomon, Scott David , Gottesman, Rebecca F.

Mayo Clinic

Stroke | October 10, 2019 | Volume: 50 | Issue: 12 | Pages: 3622-3624

10.1161/strokeaha.119.027220 | PMID 31597548 Get It

Background and Purpose— Cardiovascular disease is a known risk factor for cognitive decline, although the mechanisms remain unclear. We hypothesize that Aβ (β-amyloid), a core pathology of Alzheimer's disease, will be associated with subclinical cardiac structure and function echocardiogram indices. Methods— Three hundred six nondemented participants from the ARIC study (Atherosclerosis Risk in Communities Study) underwent florbetapir positron emission tomography and 2D echocardiography (echo). Cross-sectional associations between echo markers of left ventricular structure and function and global cortical Aβ (≥1.2 standardized uptake value ratio were evaluated using multivariable logistic regression with interaction terms when appropriate. Results— Participants ranged in age from 67 to 88 years, were 57% female and 42% black. Per 1 cm increase in end-diastolic left ventricular diameter, the odds of elevated florbetapir standardized uptake value ratio doubled (odds ratio, 2.04 [95% CI, 1.10–3.77]), with similar findings when excluding mild cognitive impairment (odds ratio, 2.61 [95% CI, 1.22–5.59]). Conclusions— We have demonstrated a significant association between a marker of left ventricular structure and elevated florbetapir standardized uptake value ratio, identified using positron emission tomography. Ongoing prospective work will help determine if changes in cardiac structure and function either precede, or occur simultaneously with deposition of amyloid.
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
Fitzmaurice, Christina , Abate, Degu , Abbasi, Naghmeh , Abbastabar, Hedayat , Abdelalim, Ahmed , Abdoli, Amir , Abdulle, Abdishakur S. M., Abebe, Nebiyu Dereje , Abraha, Haftom Niguse , Abualhasan, Ahmed , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Afarideh, Mohsen , Afshari, Mahdi , Aghaali, Mohammad , Agius, Dominic, Agrawal, Sutapa , Ahmadi, Ayat , Ahmed, Muktar Beshir , Akbari, Mohammad Esmaeil , AlAbdulKader, Assim M. , Alahdab, Fares , Alam, Shazia , Alamene, Genet Melak, Alene, Kefyalew Addis , Alipour, Vahid, Bakeshei, Fatemeh Allah, Almadi, Majid A. , Alsharif, Ubai , Alsowaidi, Shirina, Alvis‐Guzmán, Nelson , Amini, Saeed, Anbari, Zohreh , Anber, Nahla , Andrei, Cătălina Liliana , Anjomshoa, Mina, Ansari, Fereshteh, Ansariadi, Ansariadi , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Areri, Habtamu Abera , Artaman, Al, Asfaw, Ephrem Tsegay, Ashagre, Alebachew Fasil, Assadi, Reza , Atalay, Hagos Tasew , Ataro, Zerihun , Atique, Suleman , Ávila‐Burgos, Leticia , Avokpaho, Euripide , Awasthi, Ashish , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayanore, Martin Amogre , Ayele, Henok Tadesse, Babaee, Ebrahim , Bacha, Umar, Badawi, Alaa, Bagherzadeh, Mojtaba , Bagli, Eleni , Balakrishnan, Senthilkumar , Bärnighausen, Till , Battista, Robert J., Behzadifar, Meysam, Belay, Yared Belete , Berfield, Kathleen, Berhane, Adugnaw , Bernabé, Eduardo , Beuran, Mircea , Bhakta, Nickhill , Bhattacharyya, Krittika , Biadgo, Belete , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Bisignano, Catherine, Bitew, Helen , Bjørge, Tone , Bogale, Kassawmar Angaw , Bojia, Hunduma Amensisa, Borzì, Antonio Maria , Bou-Orm, Ibrahim R. , Brenner, Hermann , Brewer, Jerry D., Briko, Andrey , Брико, Н. И. , Bustamante-Teixeira, Maria Teresa , Butt, Zahid A , Carreras, Giulia , Carvalho, Félix , Castro, Clara , Castro, Franz , Catalá-López, Ferrán , Cerin, Ester , Chaiah, Yazan , Chanie, Wagaye Fentahun, Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chauhan, Neelima Singh, Chiang, Peggy Pei-Chia, Chichiabellu, Tesfaye Yitna , Chido‐Amajuoyi, Onyema Greg , Chimed‐Ochir, Odgerel , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Crowe, Christopher S. , Curado, María Paula , Dahlawi, Saad M A , Damiani, Giovanni , Darwish, Amira Hamed , Demissie, Birhanu Wondimeneh , Demoz, Gebre Teklemariam , Derakhshani, Afshin , Deribe, Kalkidan Solomon, Desai, Rupak , Desalegn, Beruk Berhanu , Dey, Subhojit , Dhimal, Meghnath , Díaz, Daniel , Dinberu, Mesfin Tadese, Djalalinia, Shirin, Drake, Thomas M , Dubljanin, Eleonora , Duken, Eyasu Ejeta, Effiong, Andem , Eftekhari, Aziz , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Elemineh, Demelash Abewa , Elkout, Hajer , Ellenbogen, Richard G. , Elsharkawy, Aisha , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Endries, Aman Yesuf , Eshrati, Babak, Fadhil, Ibtihal , Farzadfar, Farshad , Fentahun, Netsanet , Fernandes, Eduarda , Feyissa, Garumma Tolu , Fischer, Florian , Fisher, James L. , Force, Lisa M , Freitas, Marisa , Fukumoto, Takeshi , Futran, Neal D. , Gallus, Silvano , Gankpé, Fortuné Gbètoho , Gayesa, Reta Tsegaye, Gebrehiwot, Tsegaye Tewelde , Gebremeskel, Gebreamlak Gebremedhn , Gedefaw, Getnet , Gelaw, Belayneh K., Geta, Birhanu, Getachew, Sefonias , Gezae, Kebede Embaye , Ghafourifard, Mansour , Ghajar, Alireza , Ghashghaee, Ahmad , Gholamian, Asadollah , Ginindza, Themba G. , Girmay, Alem, Gizaw, Muluken , Gomez, Ricardo Santiago , Gopalani, Sameer Vali , Gorini, Giuseppe , Goulart, Bárbara Niegia Garcia de , Grada, Ayman , Guerra, Maximiliano Ribeiro, Guimarães, André Luiz Sena , Gupta, Prakash C. , Hadkhale, Kishor , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hamidi, Samer , Hanfore, Lolemo Kelbiso , Hasankhani, Milad , Hasanzadeh, Amir , Hassen, Hamid Yimam , Hay, Simon I , Henok, Andualem , Herţeliu, Claudiu , Hoang, Chi Linh , Hole, Michael K., Hoogar, Praveen , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela, Hostiuc, Sorin , Househ, Mowafa , Hussen, Mohammedaman Mama, Ileanu, Bogdan Vasile , Ilić, Milena , Innos, Kaire , Irvani, Seyed Sina Naghibi , Iseh, Kufre Robert , Islam, Sheikh Mohammed Shariful , Balalami, Nader Jafari, Jafarinia, Morteza , Jahangiry, Leila , Jahanmehr, Nader , Jakovljević, Mihajlo, James, Spencer L , Jayaraman, Sudha , Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Jürisson, Mikk , Kamangar, Farin , Karimi, Narges , Karimian, Ansar , Kasaeian, Amir , Kasahun, Gebremicheal Gebreslassie , Kassa, Belete, Kassaw, Mesfin Wudu , Kaul, Anil, Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khalilarjmandi, Maryam, Khan, Ejaz Ahmad , Khan, Gulfaraz , Khang, Young-Ho, Khater, Amir M, Khayamzadeh, Maryam , Khazaee-Pool, Maryam , Khosravi, Mohammad Hossein , Khubchandani, Jagdish , Kianipour, Neda, Kim, Daniel , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Krohn, Kristopher J, Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kuupiel, Desmond , Lad, Deepesh , Lake, Eyasu Alem , Lakew, Ayenew Molla , Lal, Dharmesh Kumar, Lami, Faris , Lan, Qing , Lasrado, Savita , Lazarus, Jeffrey V. , Leigh, James , Leshargie, Cheru Tesema , Liao, Yu , Limenih, Miteku Andualem , Listl, Stefan , Lopukhov, Platon D , Lunevičius, Raimundas , Madadin, Mohammed , Razek, Hassan Magdy Abd El , Majeed, Azeem , Manafi, Ali, Manafi, Navid , Manamo, Wondimu Ayele, Mantovani, LG , Martini, Santi , Mashamba-Thompson, Tivani P. , Massenburg, Benjamin B. , Maswabi, Motswadi Titus, McAlinden, Colm , Meheretu, Hailemariam Abiy Alemu , Mehrotra, Ravi , Meles, Gebrekiros Gebremichael , Meles, Hagazi Gebre , Melku, Mulugeta , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Merat, Shahin , Meretoja, Tuomo J , Miazgowski, Bartosz , Miazgowski, Tomasz , Mihretie, Kebadnew Mulatu M., Miller, Ted R. , Mills, Edward J , Mir, Seyed Mostafa , Mishra, Rashmi , Moazen, Babak , Mohammad, Dara K., Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Moslem, Mohammadian, Mahdi , Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Ammas Siraj , Mohammed, Jemal , Mohammed, Shafiu , Mohebi, Farnam , Mokdad, Ali H. , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moossavi, Maryam , Moradi, Ghobad , Moradi-Joo, Mohammad , Moradpour, Farhad , Morawska, Lídia , Morgado-da-Costa, Joana, Mosapour, Abbas , Mousavi, Seyyed Meysam , Muche, Achenef Asmamaw , Muhammed, Oumer Sada , Musa, Jonah , Nabhan, Ashraf , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Nagel, Gabriele , Naik, Gurudatta , Nam, Hae‐Sung , Nazari, Javad , Negoi, Ionuţ , Neupane, Subas , Nggada, Haruna Asura , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikniaz, Leila , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Nixon, Molly R, Nnaji, Chukwudi A , Shiadeh, Malihe Nourollahpour , Obsa, Mohammed Suleiman , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olagunju, Tinuke O , Oluwasanu, Mojisola , Omonisi, Abidemi , Onwujekwe, Obinna , Oommen, Anu Mary , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakpour, Amir H. , Pană, Adrian , Park, Eun‐Kee , Patel, Shanti, Patil, Snehal T, Pennini, Alyssa, Piccinelli, Cristiano, Pillay, Julian David , Pirestani, Majid , Postma, Maarten J. , Pourmalek, Farshad , Pourshams, Akram , Prakash, Swayam , Rabiee, Navid , Radfar, Amir , Rafiei, Alireza , Rahim, Fakher , Rahimi, Mahdi , Rahman, Muhammad Aziz , Rajati, Fatemeh , Rana, Saleem M., Raoofi, Samira , Rath, Goura Kishor, Rawaf, David Laith , Reiner, Robert C. , Renzaho, André M. N. , Rezapour, Aziz, Ribeiro, Ana Isabel , Ribeiro, Daniela , Roro, Elias Merdassa , Rostami, Ali , Saad, Ragy , Sabbagh, Parisa , Saddik, Basema , Safiri, Saeid , Salahshoor, Mohammad Reza , Salehi, Farkhonde , Salem, Hosni , Salem, Marwa Rashad , Salimzadeh, Hamideh , Salomon, Joshua A. , Samy, Abdallah M , Sanabria, Juan , Santric-Milicevic, Milena M , Sartorius, Benn , Sarveazad, Arash , Sathian, Brijesh , Satpathy, Maheswar , Savic, Miloje , Sawhney, Monika, Seyedmousavi, Seyedmojtaba , Shaahmadi, Faramarz , Shabaninejad, Hosein , Shahbaz, Mohammad , Shaikh, Masood Ali, Shamshirian, Amir , Shamsizadeh, Morteza , Sharafi, Zeinab , Sharifi, Ali , Sharifi, Hamid , Shirkoohi, Reza , Shukla, Sharvari , Si, Si , Siabani, Soraya , Silva, Diego Augusto Santos , Singh, Ambrish , Sisay, Solomon , Sobngwi, Eugène , Soofi, Moslem , Soriano, Joan B. , Stathopoulou, Vasiliki, Sufiyan, Mu’awiyyah Babale , Tabarés‐Seisdedos, Rafael , Tabuchi, Takahiro , Takahashi, Ken , Tarawneh, Mohammed Rasoul , Tassew, Segen Gebremeskel , Taymoori, Parvaneh , Temsah, Mohamad‐Hani , Temsah, Omar, Tesfay, Fisaha Haile , Teshale, Manaye Yihune, Tessema, Gizachew Assefa , Thapa, Subash , Tlaye, Kenean Getaneh , Topór-Mądry, Roman , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Khanh Bao , Tsadik, Afewerki Gebremeskel , Ullah, Irfan , Vaezi, Maryam, Pérez, Patricia Varona , Vidale, Simone , Violante, Francesco Saverio , Vollset, Stein Emil, Vos, Theo , Vosoughi, Kia , Vu, Giang Thu , Vujcic, Isidora S , Wabinga, Henry, Wachamo, Tesfahun Mulatu , Wagnew, Fasil Shiferaw, Waheed, Yasir , Weldegebreal, Fitsum , Weldesamuel, Girmay Teklay, Wijeratne, Tissa , Wonde, Tewodros Eshete , Workie, Hailemariam Mekonnen , Yadav, Rajaram , Yadegar, Abbas , Yadollahpour, Ali , Yaseri, Mehdi , Yazdi‐Feyzabadi, Vahid , Yeshaneh, Alex , Yimam, Mohammed , Yisma, Engida , Younis, Mustafa Z , Zadnik, Vesna, Moghadam, Telma Zahirian , Zandian, Hamed , Zangeneh, Alireza , Zaki, Leila , Zendehdel, Kazem , Zenebe, Zerihun Menlkalew, Zewale, Taye Abuhay , Ziapour, Arash , Zodpey, Sanjay , Murray, Christopher J L , Topór‐Mądry, Roman , Deribe, Kebede , Teklay, Girmay , Wijeratne, T , Kumar, Vivek , Lazarus, Jeffrey V , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Abd-Allah, Foad , Abdel-Rahman, Omar Mohammed , Abdollahpour, Ibrahim , Abu-Raddad, Laith Jamal , Ahmadian, Elham , Ahmadpour, Ehsan , Akinyemiju, Tomi , Al‐Aly, Ziyad , Alemnew, Birhan , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Erfan , Amini, Saeed, Amoako, Yaw Ampem , Arab-Zozani, Morteza , Asayesh, Hamid , Fasil, Alebachew , Ataeinia, Bahar , Ausloos, Marcel , Balouchi, Abbas , Behzadifar, Masoud , Behzadifar, Meysam, Bekele, Bayu Begashaw , Belayneh, Yaschilal Muche , Birungi, Charles , Bleyer, Archie , Bosetti, Cristina , Carrero, Juan Jesús , Chaturvedi, Pankaj , Chehrazi, Mohammad , Constantin, María Magdalena , Crocetti, Emanuele , Daryani, Ahmad , Neves, José das , Demeke, Feleke Mekonnen , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Deribe, Kalkidan Solomon, Desta, Melaku , Dharmaratne, Samath Dhamminda , Doku, David Teye , Dubey, Manisha , Ebrahimi, Hedyeh , Sayed, Iman El , Zaki, Maysaa El Sayed , Adane, Daniel, Omrani, Vahid Fallah , Faramarzi, Mahbobeh , Farhangi, Mahdieh Abbasalizad , Farioli, Andrea , Filip, Irina , Foroutan, Masoud , Tsegaye, Reta , Gelaw, Belayneh K., Gill, Paramjit Singh , Gupta, Rahul, Haro, Josep María , Hay, Roderick J. , Henry, Nathaniel J , Hidru, Hagos Degefa , Horita, Nobuyuki , Hosgood, H. Dean, Hostiuc, Mihaela, Hussen, Mohammedaman Mama, Islami, Farhad , Jahani, Mohammad Ali , Jakovljević, Mihajlo , Javanbakht, Mehdi , Jee, Sun Ha , Jenabi, Ensiyeh , Jonnagaddala, Jitendra, Jungari, Suresh Banayya , Kabir, Ali , Karch, André , Kassa, Tesfaye , Kerbo, Amene Abebe , Khang, Young-Ho, Khatab, Khaled , Khazaei, Salman , Khoja, Abdullah T , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Vecchia, Carlo La , Lal, Dharmesh Kumar, Lauriola, Paolo , Lopez, Alan D , Magdeldin, Sameh , Maleki, Afshin , Malekzadeh, Reza , Manamo, Wondimu Ayele, Mansourian, Morteza , Mansournia, Mohammad Alì , Maroufizadeh, Saman , Mathur, Manu Raj , McKee, Martin , Mehta, Varshil , Meier, Toni , Melaku, Yohannes Adama , Melese, Addisu Dagnaw , Meštrović, Tomislav , Mulatu, Kebadnew , Mirzaei, Hamed , Mirzaei, Hamid Reza , Mohammad, Dara K., Darwesh, Aso Mohammad , Mohammadbeigi, Abolfazl , Mohammadi, Hiwa , Mohammadi, Moslem, Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Nahvijou, Azin , Najafi, Farid , Naldi, Luigi , Nasiri, Naser , Newcomb, Polly A. , Nojomi, Marzieh , Nosratnejad, Shirin , Oh, In‐Hwan , Oren, Eyal , Ota, Erika , Owolabi, Mayowa , Parsian, Hadi , Pashaei, Tahereh , Pereira, David M. , Pishgar, Farhad , Pourjafar, Hadi , Prasad, Narayan , Qorbani, Mostafa , Rabiee, Mohammad , Rana, Saleem M., Rawaf, Salman , Rezaei, Nima , Ronfani, Luca , Roshandel, Gholamreza , Saad, Ragy , Sabbagh, Parisa, Sabour, Siamak , Sahebkar, Amirhossein , Sayyah, Mehdi , Schneider, Ione Jayce Ceola , Schöttker, Ben , Šekerija, Mario , Sepanlou, Sadaf Ghajarieh , Sepehrimanesh, Masood , Sharafi, Heidar , Sharif, Mehdi , Sharma, Rajesh , Sheikh, Aziz , Silveira, Dayane Gabriele Alves , Singh, Jasvinder A. , Sitas, Freddy , Tamtaji, Omid Reza , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Teshale, Manaye Yihune, Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Vacante, Marco , Vaezi, Maryam, Veisani, Yousef , Vlassov, Vasily , Vollset, Stein Emil, Wagnew, Fasil , Wondafrash, Dawit Zewdu , Wondmieneh, Adam Belay , Yimer, Ebrahim M , Yonemoto, Naohiro , Yousefi, Bahman , Yousefifard, Mahmoud , Yu, Chuanhua , Zabeh, Erfan , Zaidi, Zoubida , Zamani, Mohammad , Olagunju, Andrew T , Bhakta, Nickhill , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

JAMA Oncology | September 27, 2019 | Volume: 5 | Issue: 12 | Pages: 1749

10.1001/jamaoncol.2019.2996 | PMID 31560378 Get It